All‐cause mortality within 30 days of surgery · people with a low platelet count
It is very uncertain whether prophylactic platelet transfusion prior to surgery changes all‐cause mortality within 30 days of surgery compared with no prophylactic platelet transfusion prior to surgery (very low certainty).
1 finding from 1 review
All‐cause mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
It is very uncertain whether surgery changes all‐cause mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days № of participants: 72 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes all‐cause mortality up to 30 days № of participants: 72 (1 RCT) compared with no prophylactic plasma transfusion before surgery/invasive… (very low certainty).
1 finding from 1 review
RR 0.38 [0.13, 1.1]
Studies not reported
Very low
All‐cause mortality · women with operable primary breast cancer
No axillary surgery showed no clear difference in all‐cause mortality compared with full axillary surgery (moderate certainty).
1 finding from 1 review
All‐cause mortality (30 days)—non‐cardiac surgery · patients with conditions requiring non‐cardiac surgery
Beta‐blocker showed no clear difference in all‐cause mortality (30 days)—non‐cardiac surgery compared with control—non‐cardiac surgery (low certainty).
1 finding from 1 review
All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (30 days)—cardiac surgery · patients with coronary heart disease and/or valvular heart disease
Beta‐blocker showed no clear difference in all‐cause mortality (30 days)—cardiac surgery compared with control—cardiac surgery (moderate certainty).
1 finding from 1 review
All‐cause mortality (within 30‐days after surgery: any reported death) · adults undergoing non‐cardiac surgery
1 finding from 1 review
All‐cause mortality (within 30‐days after surgery: any reported death) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists showed no clear difference in all‐cause mortality (within 30‐days after surgery: any reported death) compared with control (moderate certainty).
1 finding from 1 review
Composite endpoint (including all‐cause mortality, non‐fatal myocardial infarction and/or any new stroke assessed at 30 days after surgery) · people undergoing CABG (with or without valve surgery)
RIPC showed no clear difference in composite endpoint (including all‐cause mortality, non‐fatal… compared with no RIPC (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality start of surgery ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term mortality (time‐to‐event outcome): radiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event outcome): radiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).
1 finding from 1 review
Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (time‐to‐event outcome): chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
2 findings from 1 review
Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (binary): definitive chemoradiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
1 finding from 1 review